共 419 条
[1]
Virani SS(2023)2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines Circulation 148 e9-e119
[2]
Newby LK(2017)How common is residual inflammatory risk? Circ Res 120 617-619
[3]
Arnold SV(2023)Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials Lancet 401 1293-1301
[4]
Bittner V(2022)Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy Eur Heart J 43 4832-4844
[5]
Brewer LC(2022)Redefining residual inflammatory risk after acute coronary syndrome Future Cardiol 18 115-123
[6]
Demeter SH(2022)Colchicine in cardiovascular disease: in-depth review Circulation 145 61-78
[7]
Ridker PM(2021)Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation Front Immunol 12 84-98
[8]
Ridker PM(2022)Targeting the inflammasome in cardiovascular disease JACC Basic Transl Sci 7 315-327
[9]
Bhatt DL(2019)Immunity and inflammation in atherosclerosis Circ Res 124 1346-1359
[10]
Pradhan AD(2020)Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation Circ Res 126 1-11